Mitokinin
Song Liu has worked in a variety of roles in the scientific field. From 2020 to present, they have been a Senior Scientist and Scientist II at Mitokinin Inc. Prior to that, they were a Senior Scientist at IGeneX, Inc from 2015 to 2020. From 2009 to 2015, they were a Research Scientist and Postdoctoral Fellow at Stanford University School of Medicine. From 2007 to 2009, they were a Postdoctoral Fellow at Rice University.
Song Liu received a B.S. in Molecular Biology from the University of Science and Technology of China between 1995 and 2000. Song then went on to earn a Ph.D. in Biochemistry and Cell Biology from Rice University between 2000 and 2007.
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.